Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
相关临床试验
11
0 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
2011
已完成
8
72.7%
招募中
1
9.1%
终止
1
9.1%
撤回
1
9.1%
- Avalo Therapeutics has completed enrollment of approximately 250 adults in its Phase 2 LOTUS trial evaluating AVTX-009 for moderate to severe hidradenitis suppurativa. - The global trial compares subcutaneous bi-weekly and monthly dosing regimens of AVTX-009 against placebo, with topline data expected in mid-2026. - Analysts project potential stock upside of over 200% if the drug achieves HiSCR75 response rates of 25-30%, with the company highlighting superior IL-1β inhibition as a competitive advantage. - Multiple investment firms have initiated bullish coverage, with target prices ranging from $25 to $50, reflecting confidence in the drug's therapeutic potential.
- Avalo Therapeutics has appointed Rita Jain, M.D., a rheumatologist with over two decades of biopharmaceutical leadership experience, to its Board of Directors. - The appointment comes as the company advances AVTX-009, a high-affinity anti-IL-1β monoclonal antibody, through a Phase 2 LOTUS trial for hidradenitis suppurativa. - Dr. Jain previously served as Chief Medical Officer at ChemoCentryx, where she advanced Tavneos (avacopan), a first-in-class treatment for ANCA-associated vasculitis. - The Phase 2 LOTUS trial results for hidradenitis suppurativa are expected to read out in the middle of next year.
- DelveInsight's 2025 report reveals a robust pipeline with 24+ companies developing 24+ therapies for hidradenitis suppurativa, a chronic inflammatory skin condition affecting hair follicles. - Key players including InflaRx, Novartis, UCB, and Boehringer Ingelheim are advancing treatments targeting various inflammatory pathways with monoclonal antibodies and small molecules. - Novel mechanisms of action include targeting IL-36R (spesolimab), C5a (vilobelimab), IL-17A (secukinumab), and BTK inhibition (remibrutinib), offering hope for patients with limited treatment options.
- Avalo Therapeutics has initiated the Phase 2 LOTUS trial evaluating AVTX-009, an anti-IL-1β monoclonal antibody, in approximately 180 adults with hidradenitis suppurativa, with topline data expected in 2026. - Analysts are optimistic about AVTX-009's potential, citing AbbVie's lutikizumab (IL-1α/β bispecific) Phase 2 results showing 59.5% response rates in moderate to severe HS patients who previously failed anti-TNF therapy. - Multiple financial firms have initiated coverage with Buy ratings, with Stifel projecting over $2 billion market potential in the US alone and setting a $36 price target, representing over 300% upside potential.
- Avalo Therapeutics has appointed Jennifer Riley as Chief Strategy Officer, effective January 1, 2025, to lead corporate strategy and product pipeline planning. - Riley brings over 20 years of experience in the biotech and pharmaceutical industries, including leadership roles at Biogen and her own consulting firm, Northbrook Consulting. - Her focus will be on advancing AVTX-009, an anti-IL-1β monoclonal antibody, currently in Phase 2 trials for hidradenitis suppurativa (HS), and exploring its expansion into other indications. - Avalo's Board of Directors approved the grant to Ms. Riley of a non-qualified stock option awarded to purchase 150,000 shares of its common stock, vesting over four (4) years.
- Avalo Therapeutics has dosed the first patient in its Phase 2 LOTUS trial evaluating AVTX-009 for hidradenitis suppurativa (HS). - The LOTUS trial is a randomized, double-blind, placebo-controlled study involving approximately 180 adults with moderate to severe HS. - AVTX-009, a humanized monoclonal antibody, targets interleukin-1β (IL-1β) to neutralize its activity in the inflammatory process of HS. - Topline data from the LOTUS trial is anticipated in 2026, offering a potential new treatment option for this debilitating skin condition.
